PREMIA and Lind Launch Joint Venture to Transform Clinical Trial Enrollment in Asia-Pacific with AI Technology
核心洞察
Precision Medicine Asia Limited (搜索) (PREMIA (搜索)) and Lind (搜索) announced the formation of Lind Asia (搜索), a strategic joint venture to revolutionize clinical trial enrollment across the Asia-Pacific region.
The partnership combines PREMIA (搜索)'s clinical-genomic database expertise with Lind (搜索)'s AI-powered screening platform to accelerate patient eligibility screening for clinical trials.
Lind Asia (搜索)'s platform features AI-powered patient identification, research-ready site networks, and integrated molecular profiling to support biomarker-driven trial matching.
Precision Medicine Asia, Limited (PREMIA (搜索)) and Lind (搜索) announced the formation of Lind Asia (搜索), a strategic joint venture dedicated to revolutionizing clinical trial enrollment in the Asia-Pacific region. The partnership aims to address the growing need for accurate, scalable, and automated clinical trial enrollment solutions by combining PREMIA's regional clinical-genomic infrastructure with Lind's evidence-driven AI platform.
Strategic Partnership Framework
Lind Asia (搜索) will serve as the exclusive regional partner for Lind (搜索)'s AI-powered screening platform, leveraging PREMIA (搜索)'s deep expertise in managing clinical-genomic databases to accelerate patient eligibility screening for clinical trials. The platform will be localized for healthcare institutions across Taiwan, Japan, South Korea, Singapore, and Australia.
"We are dedicated to advancing precision medicine across the Asia-Pacific region by addressing the growing need for accurate, scalable, and automated clinical trial enrollment solutions," said Wenn Sun, Founder and Managing Partner of PREMIA (搜索). "This joint venture combines our regional infrastructure with Lind (搜索)'s powerful AI platform to drastically improve recruitment efficiency, reduce screen failures, and expedite access to innovative therapies."
Platform Technology and Capabilities
Lind Asia (搜索)'s platform operates on three key pillars designed to transform clinical trial recruitment:
AI-powered patient identification analyzes both structured and unstructured electronic health record (EHR) data to identify potentially eligible patients for clinical trials. This technology enables healthcare providers to efficiently screen large patient populations and match them with appropriate studies.
Research-ready site network focuses on building a regional network of partner health systems to support multinational clinical trial enrollment. This infrastructure aims to streamline the trial process across multiple countries and healthcare systems in the Asia-Pacific region.
Integrated molecular profiling incorporates genomic and proteomic data to support biomarker-driven trial matching and targeted therapy development. This component enables precision medicine approaches by matching patients with trials based on their molecular characteristics.
Industry Impact and Implementation
Oggie Nikolic, Chief Executive Officer of Lind (搜索), emphasized the global significance of the partnership: "Lind Asia (搜索) is an important step in making evidence-driven clinical trial screening available to health systems and sponsors globally. By partnering with PREMIA (搜索), we can localize our platform for leading institutions across Asia-Pacific while supporting faster, more precise trial enrollment."
The joint venture addresses critical challenges in clinical trial recruitment, including lengthy enrollment timelines and high screen failure rates that have historically plagued the pharmaceutical industry. By automating patient identification and improving matching accuracy, the platform aims to accelerate access to innovative therapies for patients across the region.
Company Backgrounds
Lind (搜索) operates as a precision trial-matching platform that connects patients, innovators, and care providers through intuitive interfaces and advanced AI technology. The platform is designed to work at the point-of-care and supports integration with electronic health records, allowing secure, HIPAA-compliant access to patient data.
PREMIA (搜索), established in 2018, represents the first company in Asia to collaborate with hospitals in the region by providing a clinical-genomic data management platform. The company focuses on accelerating development of innovative therapeutics and diagnostics while expanding access to novel medicines and health-tech solutions for patients across Asia.
The leadership teams from both Lind (搜索) and Lind Asia (搜索) will attend the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 29 to June 2, 2026, to discuss how the platform can accelerate recruitment timelines for clinical trials.